159 related articles for article (PubMed ID: 11023974)
1. p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect.
Blagosklonny MV
FASEB J; 2000 Oct; 14(13):1901-7. PubMed ID: 11023974
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
3. [Dominant negative activity of mutated p53 proteins].
Dridi W; Krabchi K; Gadji M; Lavoie J; Bronsard M; Fetni R; Drouin R
Med Sci (Paris); 2006 Mar; 22(3):301-7. PubMed ID: 16527213
[TBL] [Abstract][Full Text] [Related]
4. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators.
Roemer K
Biol Chem; 1999; 380(7-8):879-87. PubMed ID: 10494837
[TBL] [Abstract][Full Text] [Related]
5. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of transcription, proteasome inhibitors, and DNA-damaging drugs differentially affect feedback of p53 degradation.
An WG; Chuman Y; Fojo T; Blagosklonny MV
Exp Cell Res; 1998 Oct; 244(1):54-60. PubMed ID: 9770348
[TBL] [Abstract][Full Text] [Related]
8. The stabilization mechanism of mutant-type p53 by impaired ubiquitination: the loss of wild-type p53 function and the hsp90 association.
Nagata Y; Anan T; Yoshida T; Mizukami T; Taya Y; Fujiwara T; Kato H; Saya H; Nakao M
Oncogene; 1999 Oct; 18(44):6037-49. PubMed ID: 10557093
[TBL] [Abstract][Full Text] [Related]
9. Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers.
Dearth LR; Qian H; Wang T; Baroni TE; Zeng J; Chen SW; Yi SY; Brachmann RK
Carcinogenesis; 2007 Feb; 28(2):289-98. PubMed ID: 16861262
[TBL] [Abstract][Full Text] [Related]
10. Repression of SHP-1 expression by p53 leads to trkA tyrosine phosphorylation and suppression of breast cancer cell proliferation.
Montano X
Oncogene; 2009 Oct; 28(43):3787-800. PubMed ID: 19749791
[TBL] [Abstract][Full Text] [Related]
11. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
12. [Dominant-negative inactivation of p53: the effect of the proportion between trans-dominant inhibitor and its target].
Morgunkova AA; Almazov VP; Strunina SM; Kopnin BP; Chumakov PM
Mol Biol (Mosk); 2003; 37(1):112-20. PubMed ID: 12624953
[TBL] [Abstract][Full Text] [Related]
13. Distinct regions of p53 have a differential role in transcriptional activation and repression functions.
Sang BC; Chen JY; Minna J; Barbosa MS
Oncogene; 1994 Mar; 9(3):853-9. PubMed ID: 8108128
[TBL] [Abstract][Full Text] [Related]
14. Induction of genetic instability by gain-of-function p53 cancer mutants.
Xu Y
Oncogene; 2008 Jun; 27(25):3501-7. PubMed ID: 18223686
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic mutant p53 increases Bcl-2 expression in estrogen receptor-positive breast cancer cells.
Pratt MA; White D; Kushwaha N; Tibbo E; Niu MY
Apoptosis; 2007 Apr; 12(4):657-69. PubMed ID: 17252199
[TBL] [Abstract][Full Text] [Related]
16. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
17. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional activities of mutant p53: when mutations are more than a loss.
Kim E; Deppert W
J Cell Biochem; 2004 Nov; 93(5):878-86. PubMed ID: 15449312
[TBL] [Abstract][Full Text] [Related]
19. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function.
de Vries A; Flores ER; Miranda B; Hsieh HM; van Oostrom CT; Sage J; Jacks T
Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2948-53. PubMed ID: 11867759
[TBL] [Abstract][Full Text] [Related]
20. Analysis of a mutant p53 protein arising in a medulloblastoma from a mouse transgenic for the JC virus early region.
White MK; Skowronska A; Gordon J; Del Valle L; Deshmane SL; Giordano A; Khalili K
Anticancer Res; 2006; 26(6B):4079-92. PubMed ID: 17201119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
